Medications for Opioid Use Disorder |
1) |
According to SAMHSA and NIDA, opioid addiction is best understood as: |
|
|
|
|
2) |
What has been shown to improve retention and outcomes for people with OUD? |
|
|
|
|
3) |
Methadone treatment is supported by: |
|
|
|
|
4) |
How should providers decide when to discontinue OUD medication? |
|
|
|
|
5) |
Why is medically supervised withdrawal required before starting naltrexone? |
|
|
|
|
6) |
What major policy change did SAMHSA implement in 2024 regarding opioid treatment programs (OTPs)? |
|
|
|
|
7) |
If a provider does not offer medication for OUD, what is the priority? |
|
|
|
|
8) |
Why is assessing for comorbid mental illness important in patients with OUD? |
|
|
|
|
9) |
Why is gathering social history important in OUD treatment planning? |
|
|
|
|
10) |
What does the severity of opioid withdrawal help determine? |
|
|
|
|
11) |
A negative opioid test without withdrawal symptoms most likely indicates: |
|
|
|
|
12) |
When may family members be included in treatment planning? |
|
|
|
|
13) |
At the start of methadone treatment in an OTP, how often must patients typically visit? |
|
|
|
|
14) |
Which patients may be appropriate candidates for residential treatment? |
|
|
|
|
15) |
What types of services may support patients receiving OUD medication? |
|
|
|
|
16) |
What should providers understand about relapse during recovery? |
|
|
|
|
17) |
What have short-term pilot studies shown about offering XR-NTX before release from controlled environments? |
|
|
|
|
18) |
Which option can relieve some withdrawal symptoms when opioid agonist medications are unavailable? |
|
|
|
|
19) |
Which methadone formulation is most commonly used in treatment programs? |
|
|
|
|
20) |
When do patients typically feel the full effect of their methadone dose? |
|
|
|
|
21) |
What safety advice should be given to patients beginning methadone treatment? |
|
|
|
|
22) |
Which reproductive-related side effect may occur with methadone use? |
|
|
|
|
23) |
During the first 90 days of OTP treatment, how many take-home doses are typically allowed per week? |
|
|
|
|
24) |
What is the generally recommended safety limit for the first day’s methadone dosing? |
|
|
|
|
25) |
Which factor would OTP medical directors consider before approving take-home doses? |
|
|
|
|
26) |
Who should be tested annually for hepatitis C? |
|
|
|
|
27) |
Which group is not an appropriate candidate for XR-NTX treatment? |
|
|
|
|
28) |
Why might some patients stop using illicit opioids after starting XR-NTX? |
|
|
|
|
29) |
Why should unstable patients be discouraged from stopping treatment? |
|
|
|
|
30) |
When should patients take their first buprenorphine dose during home induction? |
|
|
|
|
31) |
What is the primary goal of buprenorphine treatment? |
|
|
|
|
32) |
How should treatment success be measured? |
|
|
|
|
33) |
Why is adequate pain management important in patients with OUD? |
|
|
|
|
34) |
Can pregnant women on buprenorphine continue the medication during labor? |
|
|
|
|
35) |
How does the American Society of Addiction Medicine define addiction? |
|
|
|
|
36) |
Which of the following is a key feature of OUD per DSM-5? |
|
|
|
|
37) |
Why are longer courses of OUD medication beneficial? |
|
|
|
|
38) |
Which of the following is an example of building recovery capital? |
|
|
|
|
39) |
What is a key feature of trauma-informed care? |
|
|
|
|
40) |
What happens in the brain when opioids activate receptors and the nucleus accumbens (NAc)? |
|
|
|
|
41) |
Why do environmental cues become triggers for drug use? |
|
|
|
|
42) |
Who is especially at risk of methadone overdose? |
|
|
|
|
43) |
When do patients typically begin buprenorphine treatment? |
|
|
|
|
44) |
What can prescribers do if XR-NTX effectiveness declines before the next dose? |
|
|
|
|
45) |
What strategy can encourage patients to return to treatment after relapse? |
|
|
|
|